先前的研究表明,钙结合蛋白S100A12参与了肺部炎症性疾病的病理生理过程。然而,S100A12在社区获得性肺炎(CAP)患者中的作用仍然难以捉摸.因此,这项前瞻性队列研究的目的是评估CAP患者血清S100A12与严重程度和预后之间的关系.
我们的研究中纳入了两组239名CAP患者或239名健康对照。收集空腹血液和临床特征。一入场,采用酶联免疫吸附试验(ELISA)测定血清S100A12。
与对照受试者相比,CAP患者的血清S100A12增加。此外,血清S100A12根据CAP的严重程度升高。相关分析提示血清S100A12水平与血常规指标相关,肾功能标志物,CAP患者的炎性细胞因子和其他临床参数。此外,线性和逻辑回归分析显示,血清S100A12与CAP患者的严重程度评分呈正相关.此外,通过一项随访研究,探讨了高血清S100A12与预后的关系.入院时血清S100A12升高会增加CAP患者住院期间死亡和住院的风险。
CAP患者入院时血清S100A12升高与严重程度和不良预后呈正相关,提示S100A12可能参与了CAP的病理生理过程。血清S100A12的滴度可用作CAP患者中诊断和预后的生物标志物。
Previous studies indicated the calcium-binding protein S100A12 to be involved in the pathophysiology of pulmonary inflammatory diseases. However, the role of S100A12 has remained elusive in patients with community-acquired pneumonia (CAP). Therefore, the purpose of this prospective cohort study was to evaluate the association between serum S100A12 with severity and prognosis in CAP patients.
Two groups with either 239 CAP patients or 239 healthy controls were enrolled in our study. Fasting blood and clinical characteristics were collected. On admission, serum S100A12 was measured using enzyme-linked immunosorbent assay (ELISA).
Serum S100A12 was increased in CAP patients compared to control subjects. Furthermore, serum S100A12 was elevated according to the severity of CAP. Correlative analysis suggested that the level of serum S100A12 was associated with blood routine indices, renal function markers, inflammatory cytokines and other clinical parameters among CAP patients. Additionally, linear and logistical regression analyses indicated that serum S100A12 was positively associated with CAP severity scores in CAP patients. In addition, the association of high serum S100A12 and prognosis was accessed using a follow-up research. Elevated serum S100A12 on admission increased the risk of death and hospital stay in CAP patients during hospitalization.
Elevated serum S100A12 on admission is positively associated with the severity and adverse prognosis in CAP patients, suggesting that S100A12 may involve in the pathophysiological process of CAP. The titre of serum S100A12 may be used as a biomarker for diagnosis and prognosis among CAP patients.